Fleury (BSP:FLRY3) Construction In Progress: R$95 Mil (As of Mar. 2026)


BSP:FLRY3 Fleury SA BSP:FLRY3
91 GF Score
Price R$15.61
GF Value R$17.41
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fleury Construction In Progress?

Fleury BSP:FLRY3 +1.04% 91 Construction In Progress is R$95 Mil as of Mar. 2026. GuruFocus rates BSP:FLRY3 with a GF Score™ of 91/100 and a GF Value™ of R$17.41 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Fleury's quarterly construction in progress declined from Sep. 2025 (R$92 Mil) to Dec. 2025 (R$89 Mil) but then increased from Dec. 2025 (R$89 Mil) to Mar. 2026 (R$95 Mil).

Fleury's annual construction in progress increased from Dec. 2023 (R$73 Mil) to Dec. 2024 (R$88 Mil) and increased from Dec. 2024 (R$88 Mil) to Dec. 2025 (R$89 Mil).

Fleury Construction In Progress Historical Data

* Premium members only.

The historical data trend for Fleury's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fleury Construction In Progress Chart

Fleury Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.29 177.79 73.04 87.71 89.02

Fleury Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.92 62.02 91.60 89.02 94.98
BSP:FLRY3
91GF Score
Fleury SA BSP:FLRY3
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fleury Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of R$95 Mil mean?
Fleury (BSP:FLRY3) has a Construction In Progress of R$95 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Fleury and its competitors.
Is Fleury's Construction In Progress too high?
Fleury's current Construction In Progress is R$95 Mil. Overall, Fleury has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fleury's Construction In Progress compare to TMO and DHR?
Fleury's Construction In Progress of R$95 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Diagnostics & Research company?
A good Construction In Progress depends on the Medical Diagnostics & Research industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Fleury and its competitors. Fleury's current Construction In Progress is R$95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$17.41, compared to a current price of R$15.61 — trading 10.3% below its estimated fair value. The current Construction In Progress is R$95 Mil. Fleury's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current Construction In Progress is R$95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fleury (BSP:FLRY3) Overvalued in 2026?

Based on GuruFocus' analysis, Fleury stock appears to be undervalued. The current stock price of R$15.61 is trading 10.3% below its estimated GF Value™ of R$17.41. GuruFocus considers Fleury to be Modestly Undervalued.

Key valuation signals for BSP:FLRY3:

  • Construction In Progress: R$95 Mil
  • GF Value™: R$17.41 vs. price of R$15.61 (10.3% below fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fleury Business Description

Address Avenida Morumbi 8.860, 8th floor, Brooklin, Sao Paulo, SP, BRA, 04703-002
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
91GF Score

Get the complete analysis for BSP:FLRY3

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$15.61
Price
R$17.41
GF Value